OKYO Pharma Limited Ordinary Shares (OKYO) Dividend History

Company News

• OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

  OKYO Pharma plans to accelerate the clinical development of urcosimod, its drug candidate for treating neuropathic corneal pain, by analyzing data from an early closure of its Phase 2 trial. The company aims to meet with the FDA to discuss further development of urcosimod.

  GlobeNewswire Inc.
• OKYO Pharma Announces Chairman and CEO Acquire Shares

  OKYO Pharma Limited, a clinical-stage biopharmaceutical company, announced that its CEO and Executive Chairman have purchased a total of 30,000 shares of the company's ordinary shares on NASDAQ at a price of US$1.04 per share.

  GlobeNewswire Inc.
• OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

  OKYO Pharma has dosed the first patient in a Phase 2 clinical trial of its drug candidate OK-101 to treat neuropathic corneal pain, a condition with no FDA-approved treatments. The trial is designed to evaluate the safety and efficacy of OK-101 in 48 patients with neuropathic corneal pain.

  GlobeNewswire Inc.
• OKYO Pharma CEO Interview to Air on Bloomberg TV

  OKYO Pharma, a clinical-stage biopharmaceutical company, announced that its CEO, Dr. Gary S. Jacob, will be interviewed on Bloomberg TV. The company is developing therapies for dry eye disease and neuropathic corneal pain, with its lead candidate OK-101 showing promising results in a recent Phase 2 trial.

  GlobeNewswire Inc.
• OKYO Pharma Announces Chairman Acquires Shares

  OKYO Pharma Limited, a clinical-stage biopharmaceutical company, announced that Panetta Partners Limited, an entity in which the Executive Chairman has a beneficial interest, purchased 50,000 of the company's ordinary shares on NASDAQ at a price of US$1.05 per share.

  GlobeNewswire Inc.